In the era of biologic markers and genomic assays, the use of neoadjuvant endocrine therapy (NET) for select patients with hormone receptor-positive, HER2-negative (HR+HER2−) breast cancer is gaining popularity1. Here, ERBB2 is linked to breast carcinoma.